Canakinumab - Juvenile idiopathic arthritis
You are here : Home > Formulary Search > Canakinumab - Juvenile idiopathic arthritis
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Canakinumab
Indication :
Juvenile idiopathic arthritis
Group Name :
Keywords :
JIA
Brand Names Include :
Ilaris
Important Information :
Specialist centre only
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Indications
Below are listed other indications that Canakinumab is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Juvenile idiopathic arthritis.
- No records returned.
Committee Recommendations (1)
16 Apr 18 -
Not Set
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.